116 related articles for article (PubMed ID: 9607065)
1. DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses.
Bahloul C; Jacob Y; Tordo N; Perrin P
Vaccine; 1998 Feb; 16(4):417-25. PubMed ID: 9607065
[TBL] [Abstract][Full Text] [Related]
2. Chimeric lyssavirus glycoproteins with increased immunological potential.
Jallet C; Jacob Y; Bahloul C; Drings A; Desmezieres E; Tordo N; Perrin P
J Virol; 1999 Jan; 73(1):225-33. PubMed ID: 9847325
[TBL] [Abstract][Full Text] [Related]
3. Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines.
Desmézières E; Jacob Y; Saron MF; Delpeyroux F; Tordo N; Perrin P
J Gen Virol; 1999 Sep; 80 ( Pt 9)():2343-2351. PubMed ID: 10501486
[TBL] [Abstract][Full Text] [Related]
4. Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses.
Evans JS; Wu G; Selden D; Buczkowski H; Thorne L; Fooks AR; Banyard AC
Viruses; 2018 Mar; 10(3):. PubMed ID: 29543715
[TBL] [Abstract][Full Text] [Related]
5. Cross-Neutralization Activities of Antibodies against 18 Lyssavirus Glycoproteins.
Inoue Y; Kaku Y; Harada M; Ishijima K; Kuroda Y; Tatemoto K; Virhuez-Mendoza M; Nishino A; Yamamoto T; Inoue S; Matsuu A; Maeda K
Jpn J Infect Dis; 2024 May; 77(3):169-173. PubMed ID: 38171846
[TBL] [Abstract][Full Text] [Related]
6. Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses.
Evans JS; Selden D; Wu G; Wright E; Horton DL; Fooks AR; Banyard AC
J Gen Virol; 2018 Feb; 99(2):169-180. PubMed ID: 29300155
[TBL] [Abstract][Full Text] [Related]
7. Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species.
Malerczyk C; Freuling C; Gniel D; Giesen A; Selhorst T; Müller T
Hum Vaccin Immunother; 2014; 10(10):2799-804. PubMed ID: 25483634
[TBL] [Abstract][Full Text] [Related]
8. DNA-based immunisation against rabies and rabies-related viruses: towards multivalent vaccines.
Perrin P; Jacob Y; Desmézières E; Tordo N
Dev Biol (Basel); 2000; 104():151-7. PubMed ID: 11713814
[TBL] [Abstract][Full Text] [Related]
9. Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes.
Weyer J; Kuzmin IV; Rupprecht CE; Nel LH
Epidemiol Infect; 2008 May; 136(5):670-8. PubMed ID: 17588277
[TBL] [Abstract][Full Text] [Related]
10. Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity.
Badrane H; Bahloul C; Perrin P; Tordo N
J Virol; 2001 Apr; 75(7):3268-76. PubMed ID: 11238853
[TBL] [Abstract][Full Text] [Related]
11. Rabies: epidemiological tendencies and control tools.
Tordo N; Bahloul C; Jacob Y; Jallet C; Perrin P; Badrane H
Dev Biol (Basel); 2006; 125():3-13. PubMed ID: 16878455
[TBL] [Abstract][Full Text] [Related]
12. Cross-Protection of Inactivated Rabies Vaccines for Veterinary Use against Bat Lyssaviruses Occurring in Europe.
Servat A; Wasniewski M; Cliquet F
Viruses; 2019 Oct; 11(10):. PubMed ID: 31614675
[TBL] [Abstract][Full Text] [Related]
13. Immunization of dogs with a DNA vaccine induces protection against rabies virus.
Perrin P; Jacob Y; Aguilar-Sétien A; Loza-Rubio E; Jallet C; Desmézières E; Aubert M; Cliquet F; Tordo N
Vaccine; 1999 Oct; 18(5-6):479-86. PubMed ID: 10519937
[TBL] [Abstract][Full Text] [Related]
14. Antigenic characterisation of lyssaviruses in South Africa.
Ngoepe E; Fehlner-Gardiner C; Wandeler A; Sabeta C
Onderstepoort J Vet Res; 2014 Sep; 81(1):. PubMed ID: 25685866
[TBL] [Abstract][Full Text] [Related]
15. Evidence of Lagos bat virus circulation among Nigerian fruit bats.
Dzikwi AA; Kuzmin II; Umoh JU; Kwaga JK; Ahmad AA; Rupprecht CE
J Wildl Dis; 2010 Jan; 46(1):267-71. PubMed ID: 20090042
[TBL] [Abstract][Full Text] [Related]
16. Differential stability and fusion activity of Lyssavirus glycoprotein trimers.
Desmézières E; Maillard AP; Gaudin Y; Tordo N; Perrin P
Virus Res; 2003 Feb; 91(2):181-7. PubMed ID: 12573496
[TBL] [Abstract][Full Text] [Related]
17. Protective activity of a murine monoclonal antibody against European bat lyssavirus 1 (EBL1) infection in mice.
Montaño-Hirose JA; Lafage M; Weber P; Badrane H; Tordo N; Lafon M
Vaccine; 1993 Sep; 11(12):1259-66. PubMed ID: 8256507
[TBL] [Abstract][Full Text] [Related]
18. The antigen-specific cell-mediated immune response in mice is suppressed by infection with pathogenic lyssaviruses.
Perrin P; Tino de Franco M; Jallet C; Fouque F; Morgeaux S; Tordo N; Colle JH
Res Virol; 1996; 147(5):289-99. PubMed ID: 8880998
[TBL] [Abstract][Full Text] [Related]
19. Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups.
Fisher CR; Lowe DE; Smith TG; Yang Y; Hutson CL; Wirblich C; Cingolani G; Schnell MJ
Cell Rep; 2020 Jul; 32(3):107920. PubMed ID: 32697993
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactive antigenicity of nucleoproteins of lyssaviruses recognized by a monospecific antirabies virus nucleoprotein antiserum on paraffin sections of formalin-fixed tissues.
Inoue S; Sato Y; Hasegawa H; Noguchi A; Yamada A; Kurata T; Iwasaki T
Pathol Int; 2003 Aug; 53(8):525-33. PubMed ID: 12895231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
